S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
66,000% upside on tiny biotech? (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
66,000% upside on tiny biotech? (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
66,000% upside on tiny biotech? (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
66,000% upside on tiny biotech? (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News

$53.77
+1.14 (+2.17%)
(As of 09/22/2023 ET)
Compare
Today's Range
$52.75
$54.73
50-Day Range
$52.63
$63.52
52-Week Range
$42.01
$67.05
Volume
612,087 shs
Average Volume
605,342 shs
Market Capitalization
$5.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.78

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
46.5% Upside
$78.78 Price Target
Short Interest
Bearish
2.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
0.56mentions of Intra-Cellular Therapies in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$6.36 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.08) to ($0.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

230th out of 965 stocks

Pharmaceutical Preparations Industry

91st out of 456 stocks


ITCI stock logo

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI Price History

ITCI Stock News Headlines

Experts: NVIDIA Now "Too Big to Succeed"
Several of the market’s top analysts are sounding the alarm that NVIDIA’s share price may have reached its breaking point.
ATTENTION: Digital Dollar Could Send this $0.25 Play Skyrocketing
In just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.
Intra-Cellular Therapies Q2 2023 Earnings Preview
ITCI Jul 2023 65.000 call
Analyst Expectations for Intra-Cellular Therapies's Future
See More Headlines
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Company Calendar

Last Earnings
8/03/2023
Today
9/24/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITCI
Employees
561
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$78.78
High Stock Price Forecast
$98.00
Low Stock Price Forecast
$62.00
Forecasted Upside/Downside
+46.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-256,260,000.00
Pretax Margin
-50.36%

Debt

Sales & Book Value

Annual Sales
$250.31 million
Book Value
$6.93 per share

Miscellaneous

Free Float
92,665,000
Market Cap
$5.16 billion
Optionable
Optionable
Beta
1.10
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Sharon Mates Ph.D. (Age 70)
    Co-Founder, Chairman, CEO & Pres
    Comp: $2.23M
  • Mr. Lawrence J. Hineline CPA (Age 67)
    CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec.
    Comp: $820.53k
  • Mr. Michael I. Halstead J.D. (Age 50)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $983.65k
  • Dr. Suresh K. Durgam M.D. (Age 54)
    Exec. VP & Chief Medical Officer
    Comp: $961.84k
  • Mr. Mark NeumannMr. Mark Neumann (Age 60)
    EVP & Chief Commercial Officer
    Comp: $998.36k
  • Dr. Robert E. Davis Ph.D. (Age 72)
    Sr. VP & Chief Scientific Officer
  • Mr. Juan Fernando Sanchez (Age 52)
    VP of Corp. Communications & Investor Relations
  • Ms. Karen Patruno Sheehy Esq. (Age 61)
    Sr. VP & Chief Compliance Officer
  • Dr. Michael Olchaskey
    Sr. VP & Head of Regulatory Affairs
  • Mr. John A. Bardi
    Sr. VP of Market Access, Policy & Gov. Affairs













ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings
or view top-rated stocks.

What is Intra-Cellular Therapies' stock price forecast for 2023?

8 equities research analysts have issued 12 month target prices for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $62.00 to $98.00. On average, they expect the company's stock price to reach $78.78 in the next year. This suggests a possible upside of 46.5% from the stock's current price.
View analysts price targets for ITCI
or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2023?

Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI stock has increased by 1.6% and is now trading at $53.77.
View the best growth stocks for 2023 here
.

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ITCI earnings forecast
.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.17. The biopharmaceutical company had revenue of $110.80 million for the quarter, compared to analysts' expectations of $106.45 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 28.63% and a negative net margin of 50.40%. The business's revenue for the quarter was up 99.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.92) EPS.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.91%), Wasatch Advisors LP (3.63%), Bellevue Group AG (3.34%), State Street Corp (2.20%), Alliancebernstein L.P. (2.13%) and JPMorgan Chase & Co. (2.06%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends
.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $53.77.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.16 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

The company employs 561 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -